Rxsight-Co-Präsident Ilya Goldshleger acquires Aktien in a value of 154,001 US Dollars from Investing.com

Ilya Goldshleger, Co-President and Chief Operating Officer of RxSight, Inc. (NASDAQ:RXST), which has 3,100 Aktien des Unternehmens veräußert. The transaction was executed at a weight of US$49.68 for Action, and raised US$154,001. Der Verkauf wurde im Rahmen eines vorher festgelegten Rule 10b5-1 Handelsplans durchgeführt.

You will receive a purchase price of 15.08 US dollars per piece. This transaction has a value of 46,748 US dollars and war with the Vergütungspakets.

After the transactions have stopped the Goldshleger directly 42,246 Aktien, 1,372 Aktien are received indirectly from the Ehefrau contents.

In others, the Entwicklungen verzeichnete RxSight Inc. a 68% interest rate increase to US$34.9 million in the quarter of 2024. These devices are mainly used through the use of Light Adjustable Lens (LAL) and Light Delivery Devices (LDDs). Information about the future forecast for the future 2024. Analysts from Stifel, BTIG and Needham, have had their best Kaufempfehlungen for the best RxSight-Action, were their reporters in the analysis of the uninteresting cases. While RxSight exceeds Umsatz estimates, a value forecast of US$37 and US$38 million is made.

RxSight’s achievement of FDA false refraction analysis certification for the LAL+ marked its commercial expansion through the end of 2024 in the world. The complexity of the different European markets strives for these external aspects, including international developments.

InvestingPro Acknowledgment

RxSight, Inc. (NASDAQ:RXST) said that a brand has received a financial loan, which has the strong debt. Laut InvestingPro-Daten continues to invest the shares in the last month of the 2024 quarter at 71.9%, with a quarter of the shares at 67.65% in the 2024 quarter. This robust waitlist is unique with the high returns of the month gentlemen im years ago, was like one of the InvestingPro-Tipps reviewed.

Trotz des young insider sales by co-president and COO Ilya Goldshleger has given the RxSight promotion a beachy style. The promotion’s trend was down 109.54% for a year, but it was a major setback. This performance is boosted by another InvestingPro tip, which offers a strong Rendite that has been enjoyed for years.

Would-be investors are likely to be left stranded, with RxSight trading at a high price-to-book valuation of 7.24, gemäß InvestingPro-Daten. These assessments, in the form of an InvestingPro-Tipp analysis, those analysts do not plan to make their companies profitable in those years, while pointing out that the announcement represents a significant depreciation.

For a fresh analysis, InvestingPro offers 8 other tips for RxSight, which provide better financial coverage and market position of the world. These sister-related issues may focus on the interests of investors, the attention to young insider transactions and the control of the financing of foreign companies.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.